UnitedHealth stock set for its strongest run of the year; Time to buy UNH?

UnitedHealth Group (UNH) shares, having endured a turbulent 2025 with over 40% decline from highs due to surging medical costs and subsequent guidance cuts (EPS reset to $16), are now entering a historically strong seasonal period and have recently gained over 11%. While Q2 revenue grew 13%, operating expenses surged nearly 17%, compressing margins; however, the stock benefits from superinvestor backing. Future performance critically depends on UNH's ability to manage costs effectively and deliver consistent earnings amidst persistent downside risks.

Analysis

UnitedHealth Group (UNH) finds itself at a critical juncture, balancing a severe fundamental downturn in 2025 against several emerging positive catalysts. The stock has erased more than 40% of its value from recent highs, driven by significant earnings disappointments and guidance cuts. Specifically, the company suspended and then reinstated its full-year outlook with a lower adjusted EPS target of at least $16, citing surging medical costs from higher Medicare Advantage utilization. This margin pressure is evident in Q2 results, where a resilient 13% year-over-year revenue increase to $111.6 billion was overshadowed by a nearly 17% surge in operating expenses. Conversely, several factors support a more bullish outlook. The stock has recently gained significant momentum, rising over 11% in the past month, and is entering a historically powerful seasonal stretch, with October and November delivering positive returns 70% and 75% of the time, respectively, over the last two decades. Furthermore, the continued backing of prominent investors such as Warren Buffett and Michael Burry suggests a belief in the company's long-term value proposition despite the near-term operational challenges. The stock's future trajectory is therefore contingent on whether management can effectively control costs and stabilize earnings, which would allow it to capitalize on these seasonal and momentum-based tailwinds.

Key Decisions for Investors

• Given the stock's significant pullback of over 40% and recent momentum, investors with a higher risk tolerance might view the current level as a tactical entry point to capitalize on the historically strong seasonal performance in October and November.
• Investors should prioritize monitoring the company's operating margin and medical cost trends in upcoming earnings reports, as the nearly 17% surge in Q2 operating expenses remains the primary fundamental headwind.
• The stability of the reinstated guidance is paramount; any further downward revisions to the adjusted EPS target of at least $16 would be a strong negative signal, likely overriding any positive seasonal factors and signaling continued downside risk.